CERS
CERUS CORP
NASDAQ · Healthcare · Medical - Devices · US
$2.47
+5.34%Year over year
Reported trailing growth
- Revenue
- +13.7%
- EBITDA
- +112.3%
- EBIT
- +83.6%
- EPS
- +54.2%
- Free cash flow
- +194.0%
- Operating cash flow
- -1.9%
Forward estimates
Based on analyst estimates
- Revenue
- +18.8%
- EBITDA
- +309.0%
- EPS
- +48.5%
Three-year CAGR
- Revenue
- +8.4%
- EBITDA
- +45.0%
- EBIT
- +39.0%
- Net income
- +25.3%
- EPS
- +25.5%
- Free cash flow
- +0.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026